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Abstract
Growth of the pathogenic yeast Candida albicans in sub-MIC (minimum inhibitory concentration) levels of
Cu(ClO4)2 · 6H2O and [Cu(phendio)3](ClO4)2 · 4H2O (phendio = 1,10-phenanthroline-5,6-dione) increased the
concentration of miconazole and amphotericin B required to achieve the MIC90 whereas pre-growth in AgClO4
and [Ag(phendio)2]ClO4 resulted in a small decrease in the relevant MIC90 values. The copper complexes reduce
the oxygen consumption of C. albicans while the silver complexes increase oxygen consumption. In addition, pre-
growth of cells in the copper complexes resulted in a lower ergosterol content while the silver complexes induced
an elevation in ergosterol synthesis.
The ability of copper and silver complexes to alter the susceptibility of C. albicans to miconazole and ampho-
tericin B may be influenced by their action on respiration, since reduced respiration rates correlate with reduced
cellular ergosterol which is the target for amphotericin B. Lower levels of ergosterol have previously been asso-
ciated with elevated tolerance to this drug. In the case of reduced sensitivity to miconazole, tolerance may be
mediated by lower ergosterol synthesis giving rise to fewer toxic side products once biosynthesis is inhibited by
miconazole.
Abbreviations: phendio = 1,10-phenanthroline-5,6-dione. phen = 1,10-phenanthroline
Introduction
The yeast Candida albicans is responsible for a range
of superficial and systemic diseases in the immuno-
compromised patient. Conventional therapies for the
control of these diseases rely upon the use of azole
and polyene drugs which target ergosterol biosyn-
thesis and alter membrane permeability, respectively
(White et al., 1998, Abu Salah, 1996). In recent years,
the appearance of fungal strains manifesting resistance
to conventional drugs (Canuto & Rodero, 2002) has
prompted the search for novel anti-fungals with modes
of action distinct to the existing range of anti-fungals.
Metal-based drugs represent a novel group of anti-
fungal agents with potential applications for the con-
trol of fungal infections. Previous work in our labor-
atories has demonstrated that in RPMI medium at
37oC the metal-based drugs [Cu(phen)2(mal)]·2H2O,
[Mn(phen)2(mal)]·2H2O and [Ag(phen)2]ClO4 (phen
= 1,10-phenanthroline) inhibit the growth of C. al-
bicans by around 95% at a concentration of 5 µg/ml
(McCann et al. 2000; Coyle et al. 2003a). It was
established that both metal-free phen and the metal-
phen complexes affect mitochondrial function, retard
the synthesis of cytochromes b and c and uncouple res-
piration. Treatment of fungal cells with the Cu(II) and
Ag(I) complexes resulted in a reduced amount of er-
gosterol in the cell membrane and subsequent increase
in its permeability. Cells exposed to metal-free phen
and the Cu(II) and Mn(II) complexes (but not the Ag(I)
complex) demonstrated an elevation in oxygen uptake.
The general conclusion was that the drugs damage
mitochondrial function and uncouple respiration. Fur-
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2thermore, the fact that the drugs were not uniformly
active suggested that their bioactivity had a degree of
metal-ion dependency.
More recently, metal-free phendio (phendio =
1,10-phenanthroline-5,6-dione) and the Ag(I) com-
plex [Ag(phendio)2]ClO4 have been shown to cause
extensive, non-specific DNA cleavage to C. albicans,
disrupt cell division and induce gross distortions in
fungal cell morphology (Coyle et al., 2003b). Pre-
liminary experiments on cultured human cancer cells
produced IC50 values of 0.008 µg/ml (0.04 µM)
and 0.025 µg/ml (0.40 µM) for metal-free phendio
and [Ag(phendio)2]ClO4, respectively (Coyle et al.
2003b). Studies by Igdaloff et al. (1983) revealed that
both phendio and its isomer, 1,7-phenanthroline-5,6-
dione, inhibit the growth of S49 mouse lymphona cells
and S110 mouse cells, and although it was postu-
lated that inhibition of DNA and RNA syntheses were
major components of the cytotoxic effects the phenan-
throlines were presumed to have more than one mode
of action.
Metal-based drugs have well established fungi-
static and fungicidal effects and the aim of the work
presented here was to evaluate the possibility of using
Cu (II) and Ag (I) phendio complexes in combina-
tion with azole and polyene drugs for the control of
C. albicans.
Materials and methods
Fungal isolate and culture conditions
C. albicans MEN (a kind gift from Dr. David Kerridge,
Cambridge, UK) was grown to the stationary phase
(approximately 1.5 × 108 cells/ml) at 30 ◦C overnight
in YEPD broth (2% (w/v) glucose (Sigma Aldrich
Chemical Co., Dorset, UK), 2% (w/v) bacteriological
peptone (Sigma Aldrich) and 1% (w/v) yeast extract
(Sigma Aldrich)) in an orbital incubator at 200 rpm.
Drugs
Chemicals were obtained from commercial sources
and used without further purification. Cu(ClO4)2·6H2O
was purchased from Sigma Aldrich and used without
further purification. [Cu(phendio)3](ClO4)2·4H2O
and [Ag(phendio)2]ClO4 were synthesized in accord-
ance with the procedures outlined in McCann et al.
(2003).
Anti-Candida susceptibility testing of metal-based
drugs
Solutions of water-soluble copper and silver com-
plexes were prepared by dissolving 0.02 g of the solid
in sterile distilled water to yield a stock solution of
200 µg/ml. The solutions were filter sterilised using a
Millipore membrane filter (0.45 µm). Stationary phase
cultures of C. albicans were harvested by centrifu-
gation (2220 × g for 5 min in a Beckmann GS-6
centrifuge), washed twice with PBS and resuspended
at a final density of 1 × 106 cells/ml. Cell suspension
(100 µl) was added to each well of a 96-well microtitre
plate except the first column (control medium). Serial
dilutions of metal-based drugs were added to rows of
wells to construct a concentration gradient from 50–
0.78 µg/ml and the plates were incubated at 30 ◦C
for 24 h. The absorbance at 450 nm was determined
using a MRX spectrophotometer (Dynax Technology,
Chantilly, VA, USA) and the concentration that was
capable of inhibiting growth by 90% (MIC90) relative
to the control was calculated.
Amphotericin B and miconazole susceptibility testing
Yeast cultures were grown to the stationary phase
in antibiotic medium 3 (AB 3, Oxoid) overnight at
30 ◦C and 200 rpm, harvested by centrifugation and
diluted to 1 × 106/ml. Cells (1 × 105 in 100 µl) were
added to each row of a 96-well plate containing am-
photericin B in serial dilutions (Sigma-Aldrich) from
2.5–0.0048 µg/ml in AB3 medium.
Miconazole susceptibility testing was performed
using stationary phase C. albicans that had been grown
in RPMI medium overnight (Sigma Aldrich). Cells
(100 µl of 1 × 106/ml) were added to each row of
a 96-well plate containing miconazole, serially diluted
in RPMI medium from 20–0.19 µg/ml.
All plates were incubated at 30 ◦C for 24 h and the
optical density was read at 450 nm using a MRX spec-
trophotometer (Dynax Technology, Chantilly, VA,
USA).
Oxygen consumption
Cells were grown in YEPD broth supplemented with
sub-MIC levels of silver or copper complexes at 30 ◦C
for 24 h, harvested by centrifugation and re-suspended
at a density of 1 × 108/ml in phosphate buffered saline
(PBS, pH 7.2). A Clark Type oxygen electrode (Ranks
Brothers, Cambridge, UK) was employed to determ-
ine the respiration rate of cells. The rate of oxygen
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3Fig 1. Effect of metal-based drugs on the growth of C. albicans. Cells of C. albicans were exposed to increasing concentrations of MBD and
the effect on growth after 24 h incubation was determined.
consumption is expressed as the number of µmoles of
oxygen consumed per thirty sec per 1 × 108 cells.
Sterol extraction and analysis
Sterols were extracted according to the method of
Arthington–Skaggs et al. (1999). Stationary phase
cells (1.3 g wet weight) were harvested and washed
with PBS (pH 7.2). Cells were re-suspended in 20%
(w/v) KOH and 60% (v/v) ethanol and placed in a
shaking water bath (80–90 ◦C) for 1.5 h. Heptane was
added to the solution which was then agitated for
10 sec and the aqueous layer removed. The sterol con-
tent of the hexane layer was quantified using a dual
beam spectrophotometer over the range 250–300 nm.
Statistical analysis
The Kruskal–Wallis test was performed, where appro-
priate, on all results using the SigmaStat Statistical
Analysis System (Version 1.00). Values are presented
as ± SE of the mean of data from three independent
experiments.
Results
The effect of selected Cu(II) and Ag(I) phendio
complexes on the growth of C. albicans was as-
sessed. The results indicate (Figure 1) that AgClO4
and [Ag(phendio)2]ClO4 display MIC90 values of ap-
proximately 6.0 µg/ml while Cu(ClO4)2·6H2O and
[Cu(phendio)3](ClO4)2·4H2O display MIC90 values
of >50 and 46 µg/ml, respectively. In all sub-
sequent assays, concentrations corresponding to 1/4
MIC90 values of these complexes values were em-
ployed i.e. AgClO4 and [Ag(phendio)2]ClO4 at a
concentration of 1.5 µg/ml and Cu(ClO4)2·6H2O
and [Cu(phendio)3](ClO4)2·4H2O at concentrations
of 12.5 µg/ml and 11.5 µg/ml, respectively. Sub-MIC
values were employed in all subsequent assays so that
any effect on drug susceptibility would not be due to
the fungistatic effects of these compounds
Experiments were performed to determine whether
pre-growth of C. albicans in the presence of dif-
ferent metal complexes affected the subsequent sus-
ceptibility of cells to azole and/or polyene drugs.
Cells were pre-grown in medium supplemented with
1/4 MIC90 of the Cu(II) and Ag(I) phendio com-
plexes for 24 h at 30 ◦C and harvested by centri-
fugation. Anti-fungal susceptibility assays were per-
formed as described. The results (Figure 2) in-
dicate that pre-growth of C. albicans in medium
supplemented with 12.5 µg/ml Cu(ClO4)2·6H2O
or 11.5 µg/ml [Cu(phendio)3](ClO4)2·4H2O signi-
ficantly decreases the susceptibility of C. albic-
ans to miconazole (p < 0.001) (control MIC90 =
7.94 ± 1.2 µg/ml, cells pre-grown in 1/4 MIC
Cu(ClO4)2·6H2O MIC90 = 10.9 ± 0.2 µg/ml, cells
pre-grown in 1/4 MIC [Cu(phendio)3](ClO4)2·4H2O
MIC90 = 11.4 ± 0.3 µg/ml ). In the case of the sil-
ver complexes, pre-growth of C. albicans in 1.5 µg/ml
AgClO4 or [Ag(phendio)2]ClO4 increases the suscept-
ibility of the cells to miconazole. Cells pre-grown
in 1/4 MIC90 AgClO4 show a miconazole MIC90
value of 3.24 ± 0.09 µg/ml while those pre-grown in
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4Fig 2. Susceptibilities to Miconazole of C. albicans pre-grown in the presence of sub-MIC90 levels of metal complexes. The susceptibility of
C. albicans to miconazole was determined after cells had been first pre-grown in sub- MIC90 levels of metal-based drug.
1/4 MIC90 [Ag(phendio)2]ClO4 demonstrate a MIC90
value of 4.95 ± 0.27 µg/ml.
The susceptibility of C. albicans to the polyene
drug amphotericin B was also affected following
pre-growth of the cells in medium supplemented
with copper or silver complexes at 1/4 MIC90 val-
ues (Figure 3). In the case of pre-growth in 1/4
MIC90 Cu(ClO4)2·6H2O the amount of amphoteri-
cin B required to achieve the MIC90 increases to
0.029 ± 0.007 µg/ml from 0.024 ± 0.003 µg/ml
(control) and following pre-growth in a similar con-
centration of [Cu(phendio)3](ClO4)2·4H2O increases
to 0.03 ± 0.003 µg/ml (p = 0.238). In the case
of pre-exposure to the silver complexes there is a
decrease in the amount of amphotericin B required
to achieve the MIC90. Pre-growth of C. albicans in
either of the silver complexes reduces the amount
of amphotericin B required to achieve the MIC90
from 0.024 ± 0.003 µg/ml to 0.019 ± 0.001 µg/ml
(p = 0.238) (Figure 3).
Azoles, such as miconazole, inhibit the action
of lanosterol 14α-demethylase which controls an es-
sential intermediate step in the biosynthesis of er-
gosterol (White et al., 1998, Daum et al., 1998).
In contrast, polyenes, such as amphotericin B, bind
to ergosterol in the fungal cell membrane creating
pores through which cell constituents may escape
(Abu Salah, 1996). Ergosterol biosynthesis is an oxy-
gen dependent process and also requires NADPH
which is synthesised in the aerobically respiring mi-
tochondrion. Consequently, experiments were per-
formed to establish whether the altered susceptib-
ility of C. albicans to miconazole and amphoteri-
cin B was due to the ability of the copper or sil-
ver complexes to alter respiration. The results (Fig-
ure 4) demonstrate that pre-growth of cells in 1/4
MIC90 of the copper complexes (Cu(ClO4)2·6H2O
and [Cu(phendio)3](ClO4)2·4H2O) results in a reduc-
tion in the cellular respiration rate (p < 0.001) whereas
growth of cells in the presence of the silver com-
plexes (AgClO4 and [Ag(phendio)2]ClO4) increases
the respiration rate of C. albicans (p < 0.001).
The ergosterol biosynthetic pathway is the tar-
get of the azole drugs (White et al. 1998) whilst
polyenes bind ergosterol in the cell membrane and
create pores (Abu Salah, 1996). Quantification of
ergosterol in cells grown in medium supplemented
with sub MIC90 concentrations of the metal-based
drugs demonstrated that growth in the presence of
copper complexes resulted in a reduced ergosterol
content, while growth in medium supplemented with
the silver complexes resulted in an increase in cel-
lular ergosterol (Figure 5). Interestingly, those com-
pounds that increase the respiration rate (AgClO4 and
[Ag(phendio)2]ClO4) also cause an increase in er-
gosterol content while those that depress respiration
(Cu(ClO4)2·6H2O and [Cu(phendio)3](ClO4)2·4H2O)
lead to a reduction in ergosterol content.
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5Fig 3. Susceptibilities to Amphotericin B of C. albicans pre-grown in the presence of sub-MIC90 levels of metal complexes. The susceptibility
of C. albicans to amphotericin B was determined after cells had been first pre-grown in sub- MIC90 levels of metal-based drug.
Fig 4. Respiration rates of C. albicans cells pre-grown in sub-MIC90 levels of metal complexes. The oxygen consumption rates of C. albicans
cell pre-grown in sub-MIC90 levels of metal-based drug were determined using a Rank Oxygen electrode and expressed as µmoles of oxygen
consumed per 108 cells per 30 sec.
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Fig 5. Ergosterol profiles of C. albicans cells pre-grown in
sub-MIC90 levels of metal complexes. (Representative figure). The
relative amounts of ergosterol in cells pre-treated with sub-MIC90
concentrations of metal-based drug were ascertained spectrophoto-
metrically over the range 250–300 nm.
Discussion
Metal-based drugs represent a novel group of anti-
microbial agents with potential therapeutic applica-
tions (Coyle et al. 2003a; McCann et al. 2000). With
the advent of fungal isolates manifesting resistance to
azole and polyene drugs (Canuto & Rodero, 2002)
there is a requirement for new drugs with alternative
modes of action or with the ability to increase the
efficacy of existing prescription drugs. Many metal-
based drugs display modes of action distinct to those
of the prescription anti-fungals (Coyle et al. 2003a)
possibly allowing their use where resistance to con-
ventional drugs has emerged (White et al. 1998). In
addition, their different mode(s) of action may be util-
ised by employing such drugs in conjunction with
existing drugs in order to target two (or more) sites
within the fungal cell and thus raising the possibility
of achieving the same therapeutic effect by reducing
the required amount of an azole or polyene drug.
Conventional anti-fungal drugs such as polyenes or
azoles target ergosterol in the cell membrane or the
ergosterol biosynthetic pathway, respectively. In the
work presented here we have evaluated the ability of
Cu(II) and Ag(I) phendio complexes to alter the sus-
ceptibility of C. albicans to conventional azole and
polyene drugs.
The copper and silver complexes evaluated here
demonstrated fungistatic properties but for this work
sub-MIC90 values were employed to ascertain their
effect on the sensitivity of C. albicans to the conven-
tional antifungal drugs. Sub-MIC levels were chosen
to ensure that the observed effect was not due to the
fungistatic actions of the metal complex. When cells
are pre-grown in sub-MIC90 levels of the silver or
copper complexes and then assessed for their response
to miconazole or amphotericin B there is evidence of
alterations in susceptibility. Pre-growth in 1/4 MIC90
Cu(ClO4)2·6H2O or [Cu(phendio)3](ClO4)·4H2O in-
creased the tolerance of C. albicans to miconazole
and amphotericin B, whereas pre-growth in equivalent
concentrations of AgClO4 and [Ag(phendio)2ClO4]
lowers the susceptibility of C. albicans to miconazole
and amphotericin B.
The alteration in susceptibility to miconazole and
amphotericin B may occur due to the fact that
the metal complexes which inhibit respiration (i.e.
Cu(ClO4)2·6H2O and [Cu(phendio)3](ClO4)2·4H2O)
also cause a reduction in the cellular ergosterol con-
tent. Azoles, such as miconazole, target lanosterol
14α-demethylase which regulates an intermediate step
in ergosterol biosynthesis (Morschhauser, 2002). The
azoles can kill cells by inhibiting this enzyme which
subsequently leads to a decrease in ergosterol content
of the fungal cell membrane. In addition, the inhibition
of the action of 5,6-sterol desaturase by fluconazole
leads to the accumulation of toxic intermediates (such
as 14α-methylfecosterol) which may prove fatal to the
fungal cell (Geber et al. 1995). The altered susceptib-
ility to miconazole may be due to reduced ergosterol
biosynthesis resulting in fewer toxic side products be-
ing formed once the action of the demethylase has
been inhibited by miconazole. Enhanced ergosterol
biosynthesis may inadvertently lead to greater produc-
tion of toxic side-products once the azole-mediated
inhibition of sterol biosynthesis occurs.
Reduced levels of ergosterol in the fungal cell
membrane provide fewer binding sites for amphoteri-
cin B. Consequently a higher concentration of ampho-
tericin B is required to retard the growth of the cell.
Reductions in sterol levels in C. albicans have been
identified previously as a mechanism for increased
growth in the presence of amphotericin B (Kelly et al.
1997; White et al. 1998). Disruptions of the genes in
the ergosterol biosynthesis pathway cause a decrease
in ergosterol in C. glabrata and an increase in drug
tolerance, particularly to amphotericin B (Geber et al.
1995; Vazquez et al. 1996). Inhibition of respiration
in C. albicans by erythromycin leads to a drop in er-
gosterol and a concomitant increase in tolerance to
amphotericin B (Geraghty & Kavanagh, 2003a). In
addition, disruption of mitochondrial function leads to
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synthesis (Geraghty & Kavanagh, 2003b).
The requirement for a functional mitochondrion
in ergosterol biosynthesis is well characterised and
arises from the provision of NADPH for squalene di-
merisation (Parks & Casey, 1995). In addition, Erg1
encodes squalene epoxidase, which converts squalene
to 2,3-oxidosqualene. This is an oxygen-dependent
step, and in a cell with reduced respiration there would
a consequent reduction in the synthesis of ergosterol
(Daum et al. 1998), thus leading to the reduced er-
gosterol content evident in cells exposed to the copper
complexes.
An increase in respiration, as evident when
cells are pre-grown in the presence of AgClO4 and
[Ag(phendio)2]ClO4 stimulates ergosterol production.
Thus, there is more ergosterol for amphotericin B to
bind and, as a consequence, lowering the amount of
the polyene necessary for inhibition of cell growth. In
the case of the altered sensitivity to miconazole, the
silver complexes stimulate respiration and ergosterol
biosynthesis and consequently may indirectly lead to
the generation of more toxic side-products once the
cells are exposed to miconazole.
The work presented here demonstrates that using
sub-MIC levels of copper or silver dione complexes it
is possible to alter the amount of an azole or polyene
drug required to inhibit the growth of C. albicans. This
effect appears to be mediated through alterations in
the respiration rate of the cell, thereby influencing the
amount of ergosterol synthesis. This opens the possib-
ility of utilising, non-toxic levels of silver complexes
to stimulate respiration and ergosterol production with
a concomitant reduction in the amount of miconazole
or amphotericin B required to achieve the relevant
MIC90.
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